Indian-origin cancer specialist Ravi Vij honored with US professorship for redefining blood cancer treatment

Ravi Vij, an Indian-origin physician-scientist, has achieved a prestigious academic appointment as the inaugural Jeffrey S. and Prue H. Gershman Distinguished Professor at Washington University School of Medicine in St. Louis. This honor recognizes his substantial impact on blood cancer research, patient care, and medical education.

Vij's journey began at Maulana Azad Medical College in New Delhi before he pursued advanced training in the U.S. He joined the Washington University faculty in 2000, quickly establishing himself as a leading figure in the field of hematology and oncology. His work has significantly advanced treatment options for multiple myeloma, a challenging form of blood cancer.

Over two decades, Vij has been instrumental in improving outcomes for patients through his research and clinical practice. He has led numerous clinical trials exploring innovative immunotherapies and stem cell transplantation strategies, many of which have become standard treatments. His research at Siteman Cancer Center focuses on understanding the biological mechanisms of blood cancers to develop more tailored therapies, contributing to the growing field of precision medicine.

With more than 200 scientific publications to his name, Vij's contributions extend to a deep understanding of how blood cancers develop and respond to treatment. His dedication to advancing cancer care highlights a career dedicated to improving the lives of patients battling blood cancers.